The strict substrate specificity combined with over-expression in various tumor types has motivated exploitation of legumain as a pro-drug activator in cancer treatment, for instance by adding a cleavable peptide chain to doxorubicin or auristatin [10], [19] and targeting of drug compounds using a legumain enzyme inhibitor [20]. Here, LGMN is linked to cancer.